Veracyte announced that its Prosigna breast cancer test received coverage through Palmetto GBA’s MolDX program, establishing a reimbursement path for eligible patients. This decision is significant as it creates a foundation for broader adoption and revenue generation for the test, which launched in June 2026.
Veracyte announced that its Prosigna Breast Risk of Recurrence test has secured coverage through Palmetto GBA’s MolDX program, effective August 19, 2026. This is a crucial development because it establishes a reimbursement pathway for eligible patients, which is essential for the commercial success and broader adoption of diagnostic tests in the healthcare sector. The coverage applies to postmenopausal women with early-stage ER+ breast cancer meeting specific Medicare criteria. This news is a significant positive for Veracyte, as it de-risks the commercialization of Prosigna and provides a clear path to revenue generation, impacting its financial outlook positively in the short to medium term. For traders, this represents a strong catalyst for VCYT, as it directly addresses a key hurdle for diagnostic product uptake.